A detailed history of Lafayette Investments, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Lafayette Investments, Inc. holds 2,242 shares of ABBV stock, worth $402,304. This represents 0.09% of its overall portfolio holdings.

Number of Shares
2,242
Previous 2,242 -0.0%
Holding current value
$402,304
Previous $384,000 15.1%
% of portfolio
0.09%
Previous 0.09%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$154.79 - $180.76 $10,525 - $12,291
-68 Reduced 2.94%
2,242 $384,000
Q3 2023

Oct 27, 2023

BUY
$133.59 - $154.65 $20,038 - $23,197
150 Added 6.94%
2,310 $344,000
Q3 2022

Oct 28, 2022

SELL
$134.21 - $153.93 $26,842 - $30,786
-200 Reduced 8.47%
2,160 $290,000
Q1 2022

May 11, 2022

SELL
$131.98 - $163.75 $85,787 - $106,437
-650 Reduced 21.59%
2,360 $383,000
Q4 2021

Feb 10, 2022

BUY
$107.43 - $135.93 $21,486 - $27,186
200 Added 7.12%
3,010 $408,000
Q2 2021

Aug 10, 2021

BUY
$105.21 - $117.21 $295,640 - $329,360
2,810 New
2,810 $317,000
Q3 2019

Oct 23, 2019

SELL
$62.98 - $75.72 $674,830 - $811,339
-10,715 Closed
0 $0
Q2 2019

Aug 12, 2019

SELL
$65.7 - $83.98 $703,975 - $899,845
-10,715 Closed
0 $0
Q1 2019

May 03, 2019

BUY
$77.14 - $90.79 $3,625 - $4,267
47 Added 0.44%
10,715 $864,000
Q4 2018

Feb 05, 2019

BUY
$77.85 - $96.01 $46,087 - $56,837
592 Added 5.88%
10,668 $983,000
Q3 2018

Nov 08, 2018

BUY
$88.91 - $98.84 $484,737 - $538,875
5,452 Added 117.91%
10,076 $953,000
Q3 2017

Nov 13, 2017

BUY
$69.85 - $89.22 $2,654 - $3,390
38 Added 0.83%
4,624 $411,000
Q2 2017

Aug 14, 2017

BUY
N/A
4,586
4,586 $333,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $317B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Lafayette Investments, Inc. Portfolio

Follow Lafayette Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lafayette Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Lafayette Investments, Inc. with notifications on news.